IL149444A0 - A composition containing an angiotensin ii antagonist for the treatment of glaucoma - Google Patents

A composition containing an angiotensin ii antagonist for the treatment of glaucoma

Info

Publication number
IL149444A0
IL149444A0 IL14944400A IL14944400A IL149444A0 IL 149444 A0 IL149444 A0 IL 149444A0 IL 14944400 A IL14944400 A IL 14944400A IL 14944400 A IL14944400 A IL 14944400A IL 149444 A0 IL149444 A0 IL 149444A0
Authority
IL
Israel
Prior art keywords
angiotensin
glaucoma
antagonist
treatment
composition containing
Prior art date
Application number
IL14944400A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL149444A0 publication Critical patent/IL149444A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
IL14944400A 1999-12-01 2000-12-01 A composition containing an angiotensin ii antagonist for the treatment of glaucoma IL149444A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34152499 1999-12-01
JP2000078769 2000-03-21
PCT/JP2000/008545 WO2001039805A1 (fr) 1999-12-01 2000-12-01 Coprescription pour le traitement du glaucome

Publications (1)

Publication Number Publication Date
IL149444A0 true IL149444A0 (en) 2002-11-10

Family

ID=26576988

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14944400A IL149444A0 (en) 1999-12-01 2000-12-01 A composition containing an angiotensin ii antagonist for the treatment of glaucoma
IL149444A IL149444A (en) 1999-12-01 2002-05-02 Preparation containing angiotensin II antagonist for the treatment of emphysema

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149444A IL149444A (en) 1999-12-01 2002-05-02 Preparation containing angiotensin II antagonist for the treatment of emphysema

Country Status (22)

Country Link
US (4) US7307096B2 (ru)
EP (3) EP1344534A3 (ru)
JP (1) JP4000505B2 (ru)
KR (3) KR20040045029A (ru)
CN (3) CN1263512C (ru)
AT (1) ATE332145T1 (ru)
AU (1) AU773110B2 (ru)
BR (1) BR0015980A (ru)
CA (1) CA2392804C (ru)
CZ (1) CZ20021829A3 (ru)
DE (1) DE60029242T2 (ru)
ES (1) ES2267586T3 (ru)
HK (1) HK1047239B (ru)
HU (1) HUP0204049A3 (ru)
IL (2) IL149444A0 (ru)
MX (1) MXPA02005505A (ru)
NO (1) NO20022584L (ru)
NZ (1) NZ518930A (ru)
PL (1) PL201783B1 (ru)
RU (4) RU2002114335A (ru)
TW (1) TWI290470B (ru)
WO (1) WO2001039805A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386611A4 (en) * 2001-04-19 2009-05-13 Teika Pharmaceutical Co Ltd MEDICINES AND MEDICAL KITS
TW200305424A (en) * 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
US20050119299A1 (en) * 2002-03-08 2005-06-02 Sankyo Company, Limited Ophthalmic solutions containing tetrazole derivatives
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP5222462B2 (ja) * 2003-08-21 2013-06-26 スキャンポ・アーゲー 眼科用組成物
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
WO2005079809A1 (ja) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. 澄明なラタノプロスト点眼液
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011138801A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
CA2860453C (en) * 2011-01-24 2020-04-28 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR101327267B1 (ko) 2012-04-26 2013-11-11 한양대학교 에리카산학협력단 엔드이펙터용 구동력 전달장치
EP3223793B1 (en) 2014-11-25 2023-06-28 Eximore Ltd. Compositions and methods for delivering a bio-active agent or bio-active agents
KR20170093839A (ko) * 2014-12-12 2017-08-16 코와 가부시키가이샤 수성 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619370A (en) 1969-04-21 1971-11-09 Frosst & Co Charles E Microbial reduction of thiadiazoles
JPS4966691A (ru) 1972-10-30 1974-06-27
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
EP0189690B1 (en) * 1984-12-12 1989-03-01 Merck & Co. Inc. Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
JP2610619B2 (ja) * 1987-07-22 1997-05-14 エーザイ株式会社 高眼圧症治療用点眼剤
JPS6426518U (ru) 1987-08-11 1989-02-15
ATE420857T1 (de) 1988-09-06 2009-01-15 Pfizer Health Ab Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
ATE114955T1 (de) 1988-09-09 1994-12-15 Draenert Klaus Hüftgelenksprothese und ihre verwendung.
EP0375299A1 (en) * 1988-12-19 1990-06-27 Merck & Co. Inc. Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
US5273976A (en) * 1989-04-06 1993-12-28 Sankyo Company, Limited Ocular hypotensive agents
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
IL104648A0 (en) 1992-02-13 1993-06-10 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a prostaglandin or prostaglandin derivative
CA2129037C (en) * 1992-02-21 1998-03-24 Thomas Robert Dean Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
DE69534339T2 (de) * 1994-02-08 2006-05-24 Novartis Ag Behandlung von normaldruckglaukom mit valsartan
HUT74734A (en) * 1994-03-16 1997-02-28 Sankyo Co Use of biphenyl methyl imidazole derivatives for producing pharmaceutical compositions having ocular tension derpessant activity
CA2185524C (en) * 1994-03-16 2006-12-05 Tomihisa Yokoyama Ocular tension depressant
US5760249A (en) * 1995-08-29 1998-06-02 Merck & Co., Inc. Synthesis of hydroxysulfone and related compounds
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
ATE220333T1 (de) * 1996-04-05 2002-07-15 Takeda Chemical Industries Ltd Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin- sensitivität erhöht
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
AU725677B2 (en) 1997-05-09 2000-10-19 Mount Sinai School Of Medicine Of The City University Of New York, The 8-iso-prostaglandins for glaucoma therapy
IL146917A0 (en) * 1999-06-11 2002-08-14 Sankyo Co Composition containing angiotensin ii antagonist, boric acid and ethylenediamine tetraacetic acid

Also Published As

Publication number Publication date
RU2004111357A (ru) 2005-09-20
DE60029242T2 (de) 2007-07-05
RU2004111358A (ru) 2005-09-20
CN1615880A (zh) 2005-05-18
CN1615879A (zh) 2005-05-18
US20030040529A1 (en) 2003-02-27
DE60029242D1 (de) 2006-08-17
NO20022584L (no) 2002-07-29
US20080221184A1 (en) 2008-09-11
EP1234582A4 (en) 2003-05-07
NZ518930A (en) 2003-09-26
KR20040045028A (ko) 2004-05-31
EP1344534A3 (en) 2004-01-02
HUP0204049A3 (en) 2006-07-28
JP4000505B2 (ja) 2007-10-31
ATE332145T1 (de) 2006-07-15
HK1047239A1 (en) 2003-02-14
RU2004111359A (ru) 2005-09-20
CZ20021829A3 (cs) 2002-08-14
US20050014808A1 (en) 2005-01-20
RU2002114335A (ru) 2004-01-10
JP2001335511A (ja) 2001-12-04
HUP0204049A2 (hu) 2003-04-28
CA2392804C (en) 2009-02-03
CN1407903A (zh) 2003-04-02
PL355431A1 (en) 2004-04-19
KR100607430B1 (ko) 2006-08-02
KR20040045029A (ko) 2004-05-31
AU773110B2 (en) 2004-05-20
TWI290470B (en) 2007-12-01
RU2299067C2 (ru) 2007-05-20
WO2001039805A1 (fr) 2001-06-07
AU1557501A (en) 2001-06-12
US7307096B2 (en) 2007-12-11
MXPA02005505A (es) 2002-09-02
EP1344534A2 (en) 2003-09-17
IL149444A (en) 2007-06-17
EP1344535A3 (en) 2004-01-28
EP1234582B1 (en) 2006-07-05
BR0015980A (pt) 2002-11-12
ES2267586T3 (es) 2007-03-16
KR20020058034A (ko) 2002-07-12
EP1344535A2 (en) 2003-09-17
CN1263512C (zh) 2006-07-12
CA2392804A1 (en) 2001-06-07
NO20022584D0 (no) 2002-05-31
US20050043383A1 (en) 2005-02-24
HK1047239B (zh) 2006-12-08
PL201783B1 (pl) 2009-05-29
EP1234582A1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
IL149444A0 (en) A composition containing an angiotensin ii antagonist for the treatment of glaucoma
HK1157331A1 (zh) 血小板 受體抑制劑
AU1095202A (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
NO971546L (no) Reumatoid artritt-middel inneholdende IL-6-antagonist som aktiv bestanddel
IL155236A0 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
WO2002008186A3 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2004112710A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
PT2179987E (pt) Utilização de derivados carbaldeído heterocíclicos contra a anemia falciforme
WO2002064125A3 (en) Use of a farnesoid x receptor antagonist for treating hyperlipidemia
CA2378428A1 (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
GB0329620D0 (en) EP2 receptor agonists
WO2002040016A3 (fr) Association d'inhibiteurs de calpaïne et de piegeurs des formes reactives de l'oxygene
WO2005065047A3 (en) Stable oral composition containing desloratadine
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
AU3476599A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
WO2002078633A3 (en) Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia
NO971053D0 (no) Terminering av strekklegeme, for bruk som strekkstag for strekksagsplattform

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed